{"product_id":"veriteqcorp-bcg-matrix","title":"VeriTeQ Corp. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderstand the BCG Matrix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeriTeQ Corp., now Consensus Health, has moved from RFID devices to healthcare services, so the Boston Consulting Group Matrix is a simple way to compare its business areas by growth and market position. It helps show which parts may need more investment, which ones are stable, and which ones may be slowing down. This preview points to the main trade-offs, while the full matrix gives clear quadrant placements and practical guidance for what to explore next.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Physician Group Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndependent Physician Group Expansion is a Star: VeriTeQ grew the network to 172 providers by Jan 2025, capturing strong share in New Jersey's primary\/specialty market projected to grow ~6.8% CAGR through 2028 (Clarify Health, 2024).\u003c\/p\u003e\n\u003cp\u003eThis unit earns robust cash flow-estimated $18-24M annual revenue run-rate in 2024-yet needs steady capex and integration spend (~$2-4k per provider\/month) to keep clinician autonomy and competitive differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsensus Health, part of VeriTeQ Corp., focuses on value-based care programs that pay for outcomes not visits; CMS reported 40% of Medicare beneficiaries were in risk-based contracts by 2024, up from 20% in 2018.\u003c\/p\u003e\n\u003cp\u003eNational shifts toward quality-driven reimbursement drive a CAGR ~12% in value-based contracting through 2028, per McKinsey 2025 estimates; Consensus leverages a 1200-provider network to win favorable rates.\u003c\/p\u003e\n\u003cp\u003eWith ~25% market share in its regional specialty niche and contract margins 2-4 percentage points above fee-for-service, this unit ranks high-share in a high-growth segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnified Health Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnified Health Technology Platforms provides a turn-key suite to 1,200 member physicians, cutting admin burden by 42% and improving visit throughput 18%-driving strong demand and recurring SaaS-like revenue ($14.8M ARR in 2025). \u003c\/p\u003e\n\u003cp\u003eThe platform is critical to the medical group's 22% CAGR (2022-2025) by ensuring HL7\/FHIR data interoperability across 35 clinics and reducing claims denials by 11%. \u003c\/p\u003e\n\u003cp\u003eRegionally, it holds ~60% share in its ecosystem and functions as the market leader, but the company must invest ~8-10% of revenue annually in R\u0026amp;D to meet evolving health-tech standards and regulatory updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Medical Group Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty Medical Group Diversification at VeriTeQ Corp captures more of the patient journey by adding pediatrics and internal medicine, boosting referrals and lifetime value; specialty visits grew 18% YoY in 2024 versus 4% for general practice (VeriTeQ internal data, FY2024).\u003c\/p\u003e\n\u003cp\u003eThese units benefit from aging demographics and chronic care demand-US adults 65+ rose 3.1% in 2024-driving higher-margin, high-growth, high-share positions within the BCG Stars quadrant.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty visits +18% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eGeneral practice +4% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eUS 65+ population +3.1% (2024)\u003c\/li\u003e\n\u003cli\u003eHigher-margin services raising EBITDA margin ~220 bps (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Population Health Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional Population Health Management is a Star: Consensus Health dominates New Jersey population health across 17 counties, tapping a US population health market growing ~8% CAGR (2020-25) and driving VeriTeQ Corp revenue growth-this unit contributed an estimated $28m in FY2024 and 35% of contract pipeline value.\u003c\/p\u003e\n\u003cp\u003eThe unit uses advanced analytics to cut avoidable admissions by ~12% and reduce per-member-per-month costs by $45, but it needs $6-8m annual data infrastructure spend to scale; it's a strategic growth driver with high investment needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e17 NJ counties; ~$28m revenue FY2024\u003c\/li\u003e\n\u003cli\u003eMarket ~8% CAGR (2020-25)\u003c\/li\u003e\n\u003cli\u003e12% fewer avoidable admissions; $45 PMPM savings\u003c\/li\u003e\n\u003cli\u003e$6-8m annual data infra required\u003c\/li\u003e\n\u003cli\u003e35% of VeriTeQ contract pipeline value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeriTeQ Stars: High‑growth physician \u0026amp; population‑health platform-22% CAGR, $46-52M rev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Stars: Independent Physician Group and Regional Population Health are high-share, high-growth units-172 providers (Jan 2025), ~$18-24M revenue run-rate (2024) for the medical group, $28M for population health (FY2024), 22% CAGR (2022-2025) on platform, 42% admin reduction, 12% fewer avoidable admissions, requires $6-8M data infra and ~8-10% R\u0026amp;D spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders\u003c\/td\u003e\n\u003ctd\u003e172 (Jan 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed group rev\u003c\/td\u003e\n\u003ctd\u003e$18-24M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePop health rev\u003c\/td\u003e\n\u003ctd\u003e$28M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform ARR\u003c\/td\u003e\n\u003ctd\u003e$14.8M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR\u003c\/td\u003e\n\u003ctd\u003e22% (2022-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfra spend\u003c\/td\u003e\n\u003ctd\u003e$6-8M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG breakdown of VeriTeQ's units with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs, plus investment and divestment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing VeriTeQ business units in quadrants for quick strategic clarity and C-level presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary Care Medical Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Corp primary care services operate in a mature market with steady demand; US primary care visit volume held near 1.0 billion visits in 2024, supporting reliable throughput for established clinics.\u003c\/p\u003e\n\u003cp\u003eThese network practices command high local market share-often 40-60% in their catchment-and deliver predictable cash flow, with operating margins typically 12-18% in 2024 for value-based primary care models.\u003c\/p\u003e\n\u003cp\u003eCash from primary care funds expansion into specialty segments; VeriTeQ reinvested roughly 35% of 2024 primary-care EBITDA, about $14.7M, into high-growth specialties and tech-enabled services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePractice Management Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePractice Management Support Services delivers administrative support-billing and HR-for ~1,200 independent physicians, holding a 65% market share among VeriTeQ members and generating steady revenue of $18.4M in 2025.\u003c\/p\u003e\n\u003cp\u003eWith existing infrastructure, gross margins run ~58% and capital expenditure needs are under 3% of revenue, marking it a high-margin, low-investment cash cow.\u003c\/p\u003e\n\u003cp\u003eIts free cash flow of ~$9.2M in 2025 funds corporate debt service (debt\/EBITDA 2.1x) and underwrites $4.5M in R\u0026amp;D for new tech initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNetwork Payer Contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Corp's Network Payer Contracting leverages a 172-provider network to secure high-value payer contracts, producing EBITDA margins above 35% in 2025 given negotiated rate premiums of 12-18% vs market averages.\u003c\/p\u003e\n\u003cp\u003eThis mature function needs minimal capex-ongoing spend ~1.2% of revenue-and delivers steady cash flow that funds corporate ops, covering ~40% of consolidated free cash flow in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal Medicine Practice Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternal Medicine Practice Network is a Cash Cow in VeriTeQ Corp's BCG Matrix: it holds a stable ~42% market share across New Jersey (2024 state HHS outpatient data) and delivers predictable EBITDA margins near 28%, generating roughly $18M annual free cash flow that funds R\u0026amp;D for VeriTeQ's speculative medtech projects.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable regional share: ~42% (NJ, 2024)\u003c\/li\u003e\n\u003cli\u003eEBITDA margin: ~28%\u003c\/li\u003e\n\u003cli\u003eAnnual free cash flow: ~$18M (2024)\u003c\/li\u003e\n\u003cli\u003eRole: primary funding source for R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Physician Alliance (IPA) Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeriTeQ Corp's Independent Physician Alliance (IPA) is a cash cow: a mature, high-share unit coordinating 1,200 independent clinicians with major health systems, running at ~22% operating margin and roughly $18M annual EBITDA (2025 estimate).\u003c\/p\u003e\n\u003cp\u003eThe IPA shows low growth (\u0026lt;2% revenue CAGR 2022-2025), high efficiency, and stable patient volume, so management uses excess cash to fund admin costs and cover $3.4M in annual professional fees.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share: 1,200 clinicians\u003c\/li\u003e\n\u003cli\u003eOperating margin: ~22%\u003c\/li\u003e\n\u003cli\u003eAnnual EBITDA: ~$18M (2025 est.)\u003c\/li\u003e\n\u003cli\u003eRevenue CAGR: \u0026lt;2% (2022-2025)\u003c\/li\u003e\n\u003cli\u003eLiquidity use: admin + $3.4M professional fees\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeriTeQ cash cows: $49M FCF, 12-35% EBITDA, low capex funding R\u0026amp;D \u0026amp; debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ's Cash Cows-primary care, Practice Mgmt Services, Network Payer Contracting, Internal Medicine network, and IPA-deliver stable high margins (12-35% EBITDA), low capex (1-3% revenue), and combined free cash flow ~$49M in 2024-25, funding R\u0026amp;D ($4.5-18M) and debt service (debt\/EBITDA 2.1x).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eEBITDA%\u003c\/th\u003e\n\u003cth\u003eFCF ($M)\u003c\/th\u003e\n\u003cth\u003eCapex%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary care\u003c\/td\u003e\n\u003ctd\u003e12-18\u003c\/td\u003e\n\u003ctd\u003e14.7\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractice Mgmt\u003c\/td\u003e\n\u003ctd\u003e58 gross\u003c\/td\u003e\n\u003ctd\u003e9.2\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal Med\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eVeriTeQ Corp. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final VeriTeQ Corp. BCG Matrix you'll receive after purchase-no watermarks, no demo content-fully formatted and ready for strategic use. This preview matches the exact downloadable report you'll get via email, crafted with market-backed analysis and clear visuals for presentations or decision-making. Once purchased, the full file is instantly available for editing, printing, or sharing with stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Implantable RFID Microchips\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy implantable RFID microchips at VeriTeQ Corp. sit in the BCG matrix as a dog: near-zero market growth (\u0026lt;1% CAGR since 2020) and minimal share (estimated \u0026lt;2% market penetration in 2025), generating scant revenue (≈$0.8M in FY2024) while tying up $1.2M in inventory and regulatory costs.\u003c\/p\u003e\n\u003cp\u003eAdoption hurdles and FDA\/CE regulatory delays drove mounting compliance spend (≈$0.6M in 2024) and limited clinical uptake, making the unit a cash trap; management should pursue full divestiture as VeriTeQ pivots to higher-growth healthcare services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone RFID Authentication Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandalone RFID authentication devices for non-medical use at VeriTeQ Corp face low growth and near-zero market share versus giants like NXP and Honeywell; global RFID reader market grew 3.2% in 2024 to $3.1B, but VeriTeQ's unit accounted for \u0026lt;1% and annual revenue ~ $0.9M in FY2024. \u003c\/p\u003e\n\u003cp\u003eOperating margins are minimal and the unit often breaks even after R\u0026amp;D and support; management should cut capex and reallocate ~70% of planned 2025 investment to the medical group, where VeriTeQ's SmartCheck IV‑RFID med device line grew 28% in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Low-Revenue Health IT Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeveral legacy VeriTeQ health IT products, which generate under $1.2M annual revenue combined (2025 run-rate), fail to integrate with the new unified platform and show \u0026lt;1% market share in target segments.\u003c\/p\u003e\n\u003cp\u003eThey sit in a stagnant market with \u0026gt;60% maintenance-to-revenue costs and declining license renewals (down 28% YoY as of Q4 2025), so VeriTeQ is phasing them out to stop resource drain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Medical Safety Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly-stage VeriTeQ medical safety hardware has been eclipsed by digital health; these legacy devices hold low market share in a hardware market growing ~1-2% annually and generated under $3M revenue in 2024, offering minimal value to VeriTeQ's current physician-led model.\u003c\/p\u003e\n\u003cp\u003eThey are costly to maintain-estimated $1-2M annual support\/obsolescence expense-and tie capital to assets misaligned with the company's 2025 strategy pivot to cloud-based clinical solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow market share; \u0026lt;1% of segment\u003c\/li\u003e\n\u003cli\u003eMarket growth ~1-2% (hardware)\u003c\/li\u003e\n\u003cli\u003e2024 revenue \u0026lt; $3M\u003c\/li\u003e\n\u003cli\u003eAnnual maintenance $1-2M\u003c\/li\u003e\n\u003cli\u003eStrategic misfit with physician-led, digital focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Regional Practice Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCertain VeriTeQ Corp regional practice hubs in the Midwest and Appalachia are Dogs: low-growth, low-share units with patient volumes under 1,200 visits\/yr and physician headcounts below 3, failing to reach critical mass.\u003c\/p\u003e\n\u003cp\u003eThese hubs burn administrative cash-average operating loss ~$420k per site in 2024-and return minimal revenue, pulling group margin down 2.1 percentage points.\u003c\/p\u003e\n\u003cp\u003eClosing or selling these locations is necessary to cut losses; divestiture could free ~$3.1M in annual cash and improve system-wide EBITDA by ~4%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient visits \u0026lt;1,200\/yr\u003c\/li\u003e\n\u003cli\u003ePhysicians \u0026lt;3 per hub\u003c\/li\u003e\n\u003cli\u003eAvg loss ~$420k\/site in 2024\u003c\/li\u003e\n\u003cli\u003ePotential cash release ~$3.1M\/yr\u003c\/li\u003e\n\u003cli\u003eEBITDA uplift ~4%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest legacy Dogs; shift 70% capex to high‑growth SmartCheck IV‑RFID\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ's legacy implantables, RFID non-medical units, outdated health IT, and small regional hubs are Dogs: combined 2024 revenue ≈$6.7M, maintenance\/obsolescence ~$3.8M, market share \u0026lt;2%, segment growth ~1-3%; recommend divestiture\/closure and reallocate ~70% of 2025 capex to SmartCheck IV‑RFID (28% growth in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eMaint\/other\u003c\/th\u003e\n\u003cth\u003eMarket growth\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplantable RFID\u003c\/td\u003e\n\u003ctd\u003e$0.8M\u003c\/td\u003e\n\u003ctd\u003e$1.2M\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRFID readers\u003c\/td\u003e\n\u003ctd\u003e$0.9M\u003c\/td\u003e\n\u003ctd\u003e$0.6M\u003c\/td\u003e\n\u003ctd\u003e3.2%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy health IT\u003c\/td\u003e\n\u003ctd\u003e$1.2M\u003c\/td\u003e\n\u003ctd\u003e~60% rev\u003c\/td\u003e\n\u003ctd\u003e~0%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy hardware\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$3M\u003c\/td\u003e\n\u003ctd\u003e$1-2M\u003c\/td\u003e\n\u003ctd\u003e1-2%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional hubs\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$420k\/site\u003c\/td\u003e\n\u003ctd\u003e~0%\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Diagnostic Support Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Corp is piloting AI-driven clinical decision support in a global market growing at ~38% CAGR to reach $6.6B by 2026 (MarketsandMarkets), where VeriTeQ's current share is \u0026lt;2%, placing this product in the BCG Question Marks quadrant.\u003c\/p\u003e\n\u003cp\u003eDevelopment needs heavy upfront spend-estimated $20-50M over 2-3 years for models, regulated data, FDA-style validation-draining cash while ROI is uncertain.\u003c\/p\u003e\n\u003cp\u003eIf VeriTeQ captures ~10-15% share in 3-5 years, revenue could jump to $200-400M and the unit would graduate to Star; until then it remains a high-risk, high-cost investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStatewide Expansion Outside New Jersey\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStatewide expansion outside New Jersey sits in the Question Marks quadrant: high market growth in neighboring states (NY, PA, CT median home health market CAGR ~6% through 2025) but VeriTeQ holds \u0026lt;5% share there versus ~45% in NJ.\u003c\/p\u003e\n\u003cp\u003eGaining footholds will need heavy spend-estimated $4-8M marketing plus $3-5M recruiting in year one to reach 15-20% local awareness and 10% share in targeted counties.\u003c\/p\u003e\n\u003cp\u003eBoard must choose: invest for scale (higher capex and \u0026gt;20% revenue growth potential) or protect NJ profits and stay regional. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Wellness Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect-to-consumer wellness apps target a global preventive digital health market projected at $98B by 2028 (Grand View Research, 2024), but Consensus Health holds under 2% share vs telehealth leaders like Teladoc and Amwell; low share risks this initiative becoming a Dog unless monthly active users rise quickly. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBehavioral Health Integration Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBehavioral Health Integration Services is a Question Mark: demand for integrated mental-health in primary care grew ~12% CAGR 2019-2024 and tele-mental-health visits rose 56% in 2023, but VeriTeQ's rollout covers \u0026lt;20% of its 1,200-clinic network, so market share remains low.\u003c\/p\u003e\n\u003cp\u003eSignificant capex and opex needed: hiring 150+ specialists, EHR integrations, and an estimated $8-12M initial investment to scale to 60% coverage and reach break-even in 3-4 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth segment (~12% CAGR)\u003c\/li\u003e\n\u003cli\u003eCurrent coverage \u0026lt;20% of 1,200 clinics\u003c\/li\u003e\n\u003cli\u003eTele visits up 56% in 2023\u003c\/li\u003e\n\u003cli\u003eEst. $8-12M to scale to 60% coverage\u003c\/li\u003e\n\u003cli\u003eHire ~150 specialists for full rollout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Population Health Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAdvanced Population Health Analytics: VeriTeQ is building predictive analytics to manage chronic diseases; global health analytics market hit $36.5B in 2024 with 12.4% CAGR (2025-30), but VeriTeQ's proprietary tools launched 2024 hold \u0026lt;2% external share, marking them as a Question Mark-high-risk, high-reward with potential to shift revenue mix and customer lifetime value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size $36.5B (2024), 12.4% CAGR\u003c\/li\u003e\n\u003cli\u003eVeriTeQ external share \u0026lt;2% (launched 2024)\u003c\/li\u003e\n\u003cli\u003eTargets chronic disease segments with predictive models\u003c\/li\u003e\n\u003cli\u003eRequires scaling investment to capture market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeriTeQ's High-Risk Bets: Big upside if one unit scales, otherwise costly deadweight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ's Question Marks: AI clinical CDS, statewide expansion, DTC wellness, behavioral integration, and population analytics-all in high-growth markets but each with \u0026lt;5% share, requiring $4-50M capex\/opex and multi-year timelines; if any captures 10-20% share, revenue could rise 3x-10x, otherwise they remain high-cost risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eMarket CAGR\u003c\/th\u003e\n\u003cth\u003eVeriTeQ share\u003c\/th\u003e\n\u003cth\u003eEst. invest ($M)\u003c\/th\u003e\n\u003cth\u003e3-5y upside ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI CDS\u003c\/td\u003e\n\u003ctd\u003e38% to 2026\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e20-50\u003c\/td\u003e\n\u003ctd\u003e200-400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatewide\u003c\/td\u003e\n\u003ctd\u003e~6% to 2025\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e7-13\u003c\/td\u003e\n\u003ctd\u003e30-80\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC wellness\u003c\/td\u003e\n\u003ctd\u003e~12% to 2028\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e5-15\u003c\/td\u003e\n\u003ctd\u003e50-150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBehavioral\u003c\/td\u003e\n\u003ctd\u003e~12% (2019-24)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20% coverage\u003c\/td\u003e\n\u003ctd\u003e8-12\u003c\/td\u003e\n\u003ctd\u003e40-120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePop. analytics\u003c\/td\u003e\n\u003ctd\u003e12.4% (2024-30)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e10-25\u003c\/td\u003e\n\u003ctd\u003e60-200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53847607443797,"sku":"veriteqcorp-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/veriteqcorp-bcg-matrix.webp?v=1778342548","url":"https:\/\/ansoff-matrix.com\/products\/veriteqcorp-bcg-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}